US biotech firm Moderna said Wednesday it had dosed its first participants in a human study of an mRNA vaccine that targets multiple strains of influenza.

The company intends to recruit 180 adults in the United States for the Phase 1/2 portion of the trial to evaluate the safety and strength of immune response to the shot, called mRNA-1010.

It is based on the same messenger ribonucleic (mRNA) technology deployed in Moderna's COVID-19 shot, which is more than 90 percent effective, and if the trial proves successful, it could lead to a new generation of more protective flu vaccines.

Read more...